Nonetheless, although obesity‐associated alterations in GH 29, insulin 30, 31 and IGF1 32 levels, together with the concomitant insulin resistance 33, have been shown to impact the function of several metabolic organs, are thought to be involved in the increased obesity‐associated cancer risk 34, 35, 36 and can negatively affect testosterone levels 37, 38, 39, the actual influence of obesity and the concurrent changes in insulin and IGF1 levels in the physiology of normal and tumoral prostate is still to be elucidated. The gene discussed is GH1; the disease is cancer.